

**Title:** Synthesis of myrocin G, the putative active form of the myrocin antitumor antibiotics.

**Authors:** Christos Economou,<sup>1</sup> Martin Tomanik,<sup>1</sup> and Seth B. Herzon<sup>1,2,\*</sup>

**Affiliations:** <sup>1</sup>Department of Chemistry, Yale University, New Haven, Connecticut 06520, United States.

<sup>2</sup>Department of Pharmacology, Yale School of Medicine, New Haven, Connecticut 06520, United States


**Email:** seth.herzon@yale.edu

**Abstract.** The antiproliferative antimicrobial fungal metabolites known as the myrocins have been proposed to cross-link DNA by double nucleotide addition. However, the nature of the DNA-reactive species is ambiguous, as myrocins have been isolated as functionally-distinct 5-hydroxy- $\gamma$ -lactone and diosphenol isomers. Based on computational studies and literature precedent, we hypothesized that the diosphenol **7** (assigned the trivial name myrocin G) is the biologically-active form of the representative isolate (+)-myrocin C (**1**). To probe this, we developed a 15-step enantioselective route to **7**. A complex fragment coupling reaction unites two synthetic precursors of similar complexity and forms the central ring of the target in a single step. In support of our hypothesis, **7** was efficiently transformed to the bis(sulfide) **6**, a product previously isolated from reactions of **1** with benzenethiol. This work provides the first direct access to the diosphenol **7**, sets the stage for elucidating the mode of interaction of the myrocins with DNA, and provides a foundation for the synthesis of other pimarane diterpenes.

**Main text:** Efforts to elucidate the mechanism of action of natural products are complicated when the metabolite can adopt two or more functionally-distinct forms. This issue is exemplified by the antiproliferative antimicrobial metabolites myrocins C (**1**)<sup>1</sup> and B (**2**),<sup>2,3</sup> fungal isolates that contain a sensitive 5-hydroxy- $\gamma$ -lactone residue (Scheme 1A, blue in **1** and **2**). Literature indicates<sup>4</sup> this substructure undergoes facile ring-opening to the corresponding diosphenol under mildly acidic or basic conditions, raising uncertainty about its fidelity under biological conditions. Consistent with this, the diosphenol isomer of **2**, (–)-myrocin A (**3**), has been identified in fungal cultures.<sup>5</sup>

Following their landmark total synthesis of (±)-myrocin C (**1**),<sup>6</sup> Danishefsky and Chu-Moyer disclosed that treatment of synthetic (±)-**1** with excess thiophenol and triethylamine generated the bis(sulfide) **6** (63%, Scheme 1B).<sup>7</sup> The mechanism for formation of **6** was proposed to comprise S<sub>N</sub>2' substitution of the tertiary hydroxyl group (**1**→**4**), isomerization to the diosphenol **5**, and addition to the resulting activated cyclopropane. This reactivity led the authors to speculate that the myrocins cross-link DNA by sequential nucleotide addition reactions.<sup>8</sup>

**Scheme 1. A.** Structures of myrocins A–C (**1–3**). **B.** Structure of the bis(sulfide) **6** and the originally proposed mechanism for its formation. **C.** The diosphenol **7** is 2.3 kcal/mol more stable than **1** and hypothesized to be the biologically-active form of **1**. **D.** Retrosynthetic analysis of **7**.




The isolation of **3** suggests the existence of an analogous diosphenol isomer of **1**, “myrocin G (**7**)”. Consistent with earlier experimental studies,<sup>4b</sup> our own DFT calculations indicate that **7** is 2.3 kcal/mol more stable than the ring isomer **1** (Scheme 1C). This stability derives from a hydrogen-bonding interaction between the hydroxyl group and the adjacent carbonyl in **7**. These data suggested to us an alternative order of events for **1**→**6** wherein ring-opening of **1** to the diosphenol **7** precedes the initial alkylation.

Motivated by this analysis, we targeted **7** as the initial entry into this natural product family. In addition, we identified the diosphenol double bond as a strategic locus that could be converted retrosynthetically to the diketone **8** in a redox-neutral fashion (Scheme 1D). Further disconnection of the C9–C10 bond by a fragment coupling reaction reveals the  $\alpha,\beta$ -cyclopropylketone **9** and the unsaturated

ketone **10** as two precursors of similar complexity. This synthetic strategy features the direct, redox-neutral installation of the C9 alcohol, high modularity, and independent introduction of the peripheral C4 and C13 quaternary centers.

The coupling fragments **9** and **10** were prepared in 3–4 steps from known compounds (Scheme 2). Beginning with the Diels–Alder adduct **11**,<sup>14</sup> Wittig olefination [potassium bis(trimethylsilyl)amide, methyl triphenylphosphonium bromide], tandem enoxysilane hydrolysis and  $\alpha$ -carbamate elimination (aqueous hydrochloric acid), and  $\alpha$ -dehydroiodination (iodine, pyridine)<sup>9</sup> provided the C-ring fragment **10** (22% over four steps). The A-ring fragment **9** was synthesized from the  $\alpha$ -ketoester **12**.<sup>10</sup> Stereoselective Robinson annulation<sup>11</sup> between **12** and acrolein diethylacetal provided the enone **13** (32%, 92% ee).  $\alpha$ -Dehydroiodination<sup>9</sup> of **13** proceeded in 97% yield. Corey–Chaykovsky cyclopropanation<sup>12</sup> (trimethylsulfoxonium iodide, sodium hydride) provided a 2.3:1 mixture of diastereomeric  $\alpha,\beta$ -cyclopropylketones. The major (desired) diastereomer **9** was isolated in 64% yield by recrystallization.

**Scheme 2.** Synthesis of the fragment coupling partners **9** and **10**. TMSE = 2-(trimethylsilyl)ethyl.




Treatment of the iodocyclopropane **9** with *iso*-propylmagnesium chloride–lithium chloride complex,<sup>13,14</sup> followed by addition of the iodoenone **10**, generated the fragment coupling product **14** (92%, 8.2:1 dr, Scheme 3). The stereoselectivity in the addition was anticipated based on the known

stereoelectronic preferences for nucleophilic addition to cycloalkanones<sup>15</sup> and consideration of non-bonded interactions in the transition state. It is noteworthy that retro-aldol reaction of **14** is precluded by the geometric constraints introduced by the cyclopropane ring.

The ring closure precursor **16** was prepared by a five-step sequence comprising Stille cross-coupling [tetrakis(triphenylphosphine)palladium-(0), copper(I) iodide, cesium fluoride] with tributyl(1-ethoxyvinyl) tin, hydrolysis of the vinyl ether product (aqueous hydrochloric acid), tandem alcohol silylation–enoxysilane formation (trimethylsilyl trifluoromethanesulfonate, triethylamine), Rubottom oxidation (3-chloroperoxybenzoic acid), and conversion of the primary alcohol to an allyl carbonate (allyl chloroformate, pyridine, 37% overall). The structure of the intermediate  $\alpha$ -hydroxyketone was confirmed by X-ray analysis.<sup>16</sup>


After much experimentation, we found that treatment of the allyl carbonate **16** with sodium *tert*-butoxide in tetrahydrofuran at 0 °C generated the diosphenol **19** (64%). Mechanistic studies suggest that **19** is formed via aldol addition (**16**→**17**), carbonate migration (**17**→**18**), and  $\beta$ -elimination. The silyl migration product **20** was isolated separately in 15% yield.

### Scheme 3. Synthesis of 19.




This cyclization cascade provides expedient access to a protected form of **7**. After some consideration, we recognized that the key fragment coupling–ring closure cascade could potentially be carried out in one flask by embedding a latent enolate nucleophile in the C-ring electrophile. Toward this end, we prepared the enoxysilane **24** by the sequence shown in Scheme 4. Beginning with the  $\alpha$ -iodoenone **10**, ketalization (ethylene glycol,  $p$ -toluenesulfonic acid) followed by lithium–halogen exchange and addition of the Weinreb amide<sup>17</sup> **21** provided the  $\alpha,\beta$ -unsaturated ketone **22** (70%). Removal of the silyl ether (tetra- $n$ -butylammonium fluoride), installation of the allyl carbonate (allyl chloroformate, pyridine), and removal of the acetal (aqueous hydrochloric acid) generated the  $\beta$ -diketone **23**. Site-selective deprotonation of **12** (lithium hexamethyldisilazide) and trapping of the resulting enolate with chlorotrimethylsilane provided the target enoxysilane **24**.

#### Scheme 4. Synthesis of the enoxysilane **24**.




Attempts to effect the fragment coupling of the enoxysilane **24** with the organomagnesium reagent derived from **9** were unsuccessful. We found, however, that lithium–halogen exchange (*n*-butyllithium,  $-78\text{ }^\circ\text{C}$ ), followed by immediate addition of the enoxysilane **24** and warming to  $0\text{ }^\circ\text{C}$  provided the fully annulated product **19** in 38% yield (Scheme 5). The modest yield of this transformation is offset to some extent by the rapid increase in molecule complexity achieved. Deprotection of **18** (tetra-*n*-butylammonium fluoride) then provided the target **7** (64%). Subjecting synthetic **7** to the conditions disclosed by Danishefsky and Chu-Moyer<sup>7</sup> provided the bis(sulfide) **6** (74%, Scheme 6). This result provides support for our hypothesis and indicates that the diosphenol **7** is a competent intermediate in the double nucleophilic addition of thiols. We reasoned that (+)-myrocin C (**1**) itself might be accessible by disrupting the diosphenol hydrogen bond, thereby making lactonization thermodynamically favorable,<sup>18</sup> although exploratory experiments toward this end were unsuccessful.

**Scheme 5.** One-step synthesis of **19** from **9** and **24**.



**Scheme 6.** Synthesis of the bis(sulfide) **6** from the diosphenol **7**.



In summary, we have developed a concise, enantioselective synthesis of “myrocin G” (**7**), the putative active form of the antiproliferative antimicrobial metabolite myrocin C (**1**). Key to the success of this approach was the development of a powerful annulation strategy that forges the central ring of the target in a single step. Future work will focus on elucidating the mode of interaction of **7** with DNA or its protein target(s) and applying this strategy to other pimarane diterpene natural products.





## Acknowledgement.

Financial support from the National Institutes of Health (Ruth L. Kirschstein National Research Service Award F31CA213964-03 to C.E.) and Yale University is gratefully acknowledged

## References.

1. (a) Hsu, Y. H.; Hirota, A.; Shima, S.; Nakagawa, M.; Nozaki, H.; Tada, T.; Nakayama, M. *Agric. Biol. Chem.* **1987**, *51*, 3455. (b) Hsu, Y. H.; Hirota, A.; Shima, S.; Nakagawa, M.; Adachi, T.; Nozaki, H.; Nakayama, M. *J. Antibiot.* **1989**, *42*, 223. (c) Nakagawa, M.; Hsu, Y. H.; Hirota, A.; Shima, S.; Nakayama, M. *J. Antibiot.* **1989**, *42*, 218.
2. (a) Hsu, Y. H.; Nakagawa, M.; Hirota, A.; Shima, S.; Nakayama, M. *Agric. Biol. Chem.* **1988**, *52*, 1305. (b) Lehr, N.-A.; Meffert, A.; Antelo, L.; Sterner, O.; Anke, H.; Weber, R. W. S. *FEMS Microbiol. Ecol* **2006**, *55*, 105.
3. For a review of pimarane diterpenes, see: Wang, X.; Yu, H.; Zhang, Y.; Lu, X.; Wang, B.; Liu, X. *Chem. Biodiversity* **2018**, *15*, e1700276.
4. (a) Langschwager, W.; Hoffmann, H. M. R. *Liebigs Ann.* **1995**, 797. (b) Zander, N.; Langschwager, W.; Hoffmann, H. M. R. *Synth. Commun.* **1996**, *26*, 4577.
5. (a) Klemke, C.; Kehraus, S.; Wright, A. D.; König, G. M. *J. Nat. Prod.* **2004**, *67*, 1058. (b) Tsukada, M.; Fukai, M.; Miki, K.; Shiraishi, T.; Suzuki, T.; Nishio, K.; Sugita, T.; Ishino, M.; Kinoshita, K.; Takahashi, K.; Shiro, M.; Koyama, K. *J. Nat. Prod.* **2011**, *74*, 1645.
6. Chu-Moyer, M. Y.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1992**, *114*, 8333.
7. Chu-Moyer, M. Y.; Danishefsky, S. J. *Tetrahedron Lett.* **1993**, *34*, 3025.
8. For a review of DNA reactive natural products, see: Wolkenberg, S. E.; Boger, D. L. *Chem. Rev.* **2002**, *102*, 2477.

9. Johnson, C. R.; Adams, J. P.; Braun, M. P.; Senanayake, C. B. W.; Wovkulich, P. M.; Uskokovic, M. R. *Tetrahedron Lett.* **1992**, *33*, 917.
10. (a) Ueda, Y.; Roberge, G.; Vinet, V. *Can. J. Chem.* **1984**, *62*, 2936. (b) Meng, Z.; Yu, H.; Li, L.; Tao, W.; Chen, H.; Wan, M.; Yang, P.; Edmonds, D. J.; Zhong, J.; Li, A. *Nat. Commun.* **2015**, *6*, 6096.
11. Xu, C.; Zhang, L.; Luo, S. *J. Org. Chem.* **2014**, *79*, 11517.
12. Corey, E. J.; Chaykovsky, M. *J. Am. Chem. Soc.* **1965**, *87*, 1353.
13. (a) Ren, H.; Krasovskiy, A.; Knochel, P. *Chem. Commun.* **2005**, 543. For a review, see: (b) Klatt, T.; Markiewicz, J. T.; Samann, C.; Knochel, P. *J. Org. Chem.* **2014**, *79*, 4253.
14. This addition drew inspiration from a related elegant fragment coupling employed by Baran and co-workers en route to (–)-maoecrystal V. See: Cernijenko, A.; Risgaard, R.; Baran, P. S. *J. Am. Chem. Soc.* **2016**, *138*, 9425.
15. Bürgi, H. B.; Dunitz, J. D.; Lehn, J. M.; Wipff, G. *Tetrahedron* **1974**, *30*, 1563.
16. See the Supporting Information.
17. Nahm, S.; Weinreb, S. M. *Tetrahedron Lett.* **1981**, *22*, 3815.
18. Calculations [B3LYP/6-31+G(d,p)] suggest the diosphenol methyl ether of **7** is 1.7 kcal/mol higher in energy than the methyl ether of **1**.